Mirum's Drug Trial Shows Significant Itch Relief in Liver Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy MIRM?
Source: stocktwits
- Clinical Trial Success: Mirum's drug volixibat achieved its primary endpoint in a mid-stage study, showing a 2.72-point improvement on a standardized scale for 111 patients with moderate-to-severe itch, significantly outperforming the placebo group's 1.08-point improvement, indicating its clinical relevance in alleviating itch associated with liver diseases.
- FDA Approval Process: Mirum plans to submit a New Drug Application in the second half of 2026 and has scheduled a pre-application meeting with the FDA, positioning volixibat as a potential therapy for PSC, a rare liver disease with no approved treatments, thus holding significant market potential.
- Positive Stock Market Reaction: Following the trial announcement, Mirum's shares closed 10% higher on Monday, marking its best performance since mid-December, reflecting investor optimism about the drug's prospects, with the stock gaining approximately 140% over the past 12 months.
- Retail Trader Sentiment Shift: On Stocktwits, retail sentiment around MIRM shifted from 'bearish' to 'extremely bullish', with message volume rising from 'normal' to 'extremely high', indicating market excitement over potential acquisition talks, with some users speculating a share price target of $160.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MIRM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MIRM
Wall Street analysts forecast MIRM stock price to fall
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 102.930
Low
81.00
Averages
102.33
High
140.00
Current: 102.930
Low
81.00
Averages
102.33
High
140.00
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mirum Pharmaceuticals Q1 2026 Earnings Call Insights
- Revenue Guidance Raised: Mirum Pharmaceuticals has raised its full-year revenue guidance for 2026 to $660 million to $680 million, reflecting strong demand for LIVMARLI in the U.S. market, which is expected to drive performance growth in the coming months.
- Clinical Trial Progress: The VISTAS study demonstrated significant improvement in pruritus with volixibat, positioning it as a potential first approved medicine in the U.S., further solidifying Mirum's market position in liver disease treatment.
- New Drug Launch Plans: The company has submitted a priority review application for zilurgisertib to the FDA, with a PDUFA date set for September 26, and if approved, it is expected to launch by year-end, potentially generating over $200 million in sales.
- Financial Performance Overview: First-quarter net product sales were approximately $160 million, and despite the impact of non-recurring expenses related to the acquisition of Bluejay Therapeutics, the company anticipates achieving positive cash flow next year, indicating strong growth potential ahead.
See More
Mirum's Drug Trial Shows Significant Itch Relief in Liver Disease
- Clinical Trial Success: Mirum's drug volixibat achieved its primary endpoint in a mid-stage study, showing a 2.72-point improvement on a standardized scale for 111 patients with moderate-to-severe itch, significantly outperforming the placebo group's 1.08-point improvement, indicating its clinical relevance in alleviating itch associated with liver diseases.
- FDA Approval Process: Mirum plans to submit a New Drug Application in the second half of 2026 and has scheduled a pre-application meeting with the FDA, positioning volixibat as a potential therapy for PSC, a rare liver disease with no approved treatments, thus holding significant market potential.
- Positive Stock Market Reaction: Following the trial announcement, Mirum's shares closed 10% higher on Monday, marking its best performance since mid-December, reflecting investor optimism about the drug's prospects, with the stock gaining approximately 140% over the past 12 months.
- Retail Trader Sentiment Shift: On Stocktwits, retail sentiment around MIRM shifted from 'bearish' to 'extremely bullish', with message volume rising from 'normal' to 'extremely high', indicating market excitement over potential acquisition talks, with some users speculating a share price target of $160.
See More
Mirum Pharmaceuticals' VISTAS Study Achieves Success
- Clinical Trial Success: Mirum Pharmaceuticals' VISTAS Phase 2b study demonstrated that Volixibat met its primary endpoint in 158 patients with primary sclerosing cholangitis, indicating its potential as the first treatment for cholestatic pruritus.
- Significant Efficacy: Patients treated with 20 mg of Volixibat twice daily showed statistically significant improvements in pruritus within two weeks, particularly in the secondary cohort with mild itch at baseline, highlighting the drug's effectiveness.
- Positive Market Reaction: In pre-market trading, Mirum's stock rose by 3.58% to $99.99, reflecting investor optimism regarding the study results, which may enhance future market performance.
- Key Conference Presentation: The full results of the VISTAS Phase 2b study will be presented at the European Association for the Study of the Liver International Liver Congress on May 30, further elevating the company's profile in liver disease treatment.
See More
Mirum Pharmaceuticals to Report VISTAS Trial Results Today
- Investor Call Scheduled: Mirum Pharmaceuticals is set to host an investor call today, May 4, 2026, to report topline results from the Phase 2b VISTAS trial, aimed at evaluating the efficacy and safety of Volixibat in treating primary sclerosing cholangitis.
- Disease Context: Primary sclerosing cholangitis is a rare and serious chronic liver disease that can lead to fibrosis, cirrhosis, and ultimately liver failure, highlighting the urgent need for effective treatment options.
- Trial Design: The VISTAS trial is a global, randomized, double-blinded, placebo-controlled study, with the primary endpoint being a reduction in pruritus measured by the Adult ItchRO scale, with an efficacy threshold set at 20 mg BID.
- Market Performance: Mirum's stock closed at $96.53 on Friday, down 0.80%, but is trading at $97.35 in the overnight market, up 0.85%, indicating investor interest in the upcoming trial results.
See More
Mirum Pharmaceuticals to Host Investor Call on VISTAS Study Results
- Investor Call Announcement: Mirum Pharmaceuticals has announced an investor call scheduled for May 4, 2026, at 8:30 a.m. ET to discuss topline results from the VISTAS study on volixibat for patients with primary sclerosing cholangitis (PSC), aimed at enhancing investor understanding of the company's R&D progress.
- Study Results Focus: The call will highlight the findings related to volixibat, an IBAT inhibitor in late-stage development for PSC and primary biliary cholangitis (PBC), which could provide new treatment options for patients, thereby potentially impacting market perception positively.
- Company Overview: Mirum Pharmaceuticals specializes in rare diseases, with a portfolio that includes approved products like LIVMARLI® and CHOLBAM®, demonstrating its commitment to delivering breakthrough therapies for overlooked conditions and showcasing deep expertise in the rare disease sector.
- Clinical Pipeline Insights: Mirum's clinical pipeline features candidates such as brelovitug for chronic hepatitis delta virus and MRM-3379 for Fragile X syndrome, reflecting the company's strategic focus on advancing high-impact medicines through disciplined execution and collaboration within the rare disease ecosystem.
See More
Mirum Pharmaceuticals' AZURE-1 Study Achieves Key Endpoint
- Clinical Trial Success: Mirum Pharmaceuticals reported that in the Phase 2b portion of its AZURE-1 study, brelovitug demonstrated strong antiviral activity at Week 24, with 100% of patients in the 300 mg weekly group and 75% in the 900 mg every four weeks group achieving a virologic response, indicating its effectiveness in treating chronic hepatitis delta virus (HDV).
- Primary Endpoint Achieved: The primary composite endpoint, which includes virologic response and normalization of liver enzyme ALT, was achieved in 45% and 35% of patients in the respective dose groups, while none in the delayed treatment group, highlighting brelovitug's therapeutic potential.
- Good Tolerability: Over the 24-week observation period, continued reductions in viral levels and liver enzyme markers were observed, supporting brelovitug's potential as a standalone therapy for HDV, potentially offering new treatment options for patients.
- Stock Price Fluctuation: Mirum's shares closed at $91.49 on Friday, down 0.50%, reflecting a relatively muted market reaction despite the positive clinical trial results, which may indicate investor caution regarding future studies and market acceptance.
See More
Mirum Pharmaceuticals Q1 2026 Earnings Call Insights
- Revenue Guidance Raised: Mirum Pharmaceuticals has raised its full-year revenue guidance for 2026 to $660 million to $680 million, reflecting strong demand for LIVMARLI in the U.S. market, which is expected to drive performance growth in the coming months.
- Clinical Trial Progress: The VISTAS study demonstrated significant improvement in pruritus with volixibat, positioning it as a potential first approved medicine in the U.S., further solidifying Mirum's market position in liver disease treatment.
- New Drug Launch Plans: The company has submitted a priority review application for zilurgisertib to the FDA, with a PDUFA date set for September 26, and if approved, it is expected to launch by year-end, potentially generating over $200 million in sales.
- Financial Performance Overview: First-quarter net product sales were approximately $160 million, and despite the impact of non-recurring expenses related to the acquisition of Bluejay Therapeutics, the company anticipates achieving positive cash flow next year, indicating strong growth potential ahead.
See More
Mirum's Drug Trial Shows Significant Itch Relief in Liver Disease
- Clinical Trial Success: Mirum's drug volixibat achieved its primary endpoint in a mid-stage study, showing a 2.72-point improvement on a standardized scale for 111 patients with moderate-to-severe itch, significantly outperforming the placebo group's 1.08-point improvement, indicating its clinical relevance in alleviating itch associated with liver diseases.
- FDA Approval Process: Mirum plans to submit a New Drug Application in the second half of 2026 and has scheduled a pre-application meeting with the FDA, positioning volixibat as a potential therapy for PSC, a rare liver disease with no approved treatments, thus holding significant market potential.
- Positive Stock Market Reaction: Following the trial announcement, Mirum's shares closed 10% higher on Monday, marking its best performance since mid-December, reflecting investor optimism about the drug's prospects, with the stock gaining approximately 140% over the past 12 months.
- Retail Trader Sentiment Shift: On Stocktwits, retail sentiment around MIRM shifted from 'bearish' to 'extremely bullish', with message volume rising from 'normal' to 'extremely high', indicating market excitement over potential acquisition talks, with some users speculating a share price target of $160.
See More
Mirum Pharmaceuticals' VISTAS Study Achieves Success
- Clinical Trial Success: Mirum Pharmaceuticals' VISTAS Phase 2b study demonstrated that Volixibat met its primary endpoint in 158 patients with primary sclerosing cholangitis, indicating its potential as the first treatment for cholestatic pruritus.
- Significant Efficacy: Patients treated with 20 mg of Volixibat twice daily showed statistically significant improvements in pruritus within two weeks, particularly in the secondary cohort with mild itch at baseline, highlighting the drug's effectiveness.
- Positive Market Reaction: In pre-market trading, Mirum's stock rose by 3.58% to $99.99, reflecting investor optimism regarding the study results, which may enhance future market performance.
- Key Conference Presentation: The full results of the VISTAS Phase 2b study will be presented at the European Association for the Study of the Liver International Liver Congress on May 30, further elevating the company's profile in liver disease treatment.
See More
Mirum Pharmaceuticals to Report VISTAS Trial Results Today
- Investor Call Scheduled: Mirum Pharmaceuticals is set to host an investor call today, May 4, 2026, to report topline results from the Phase 2b VISTAS trial, aimed at evaluating the efficacy and safety of Volixibat in treating primary sclerosing cholangitis.
- Disease Context: Primary sclerosing cholangitis is a rare and serious chronic liver disease that can lead to fibrosis, cirrhosis, and ultimately liver failure, highlighting the urgent need for effective treatment options.
- Trial Design: The VISTAS trial is a global, randomized, double-blinded, placebo-controlled study, with the primary endpoint being a reduction in pruritus measured by the Adult ItchRO scale, with an efficacy threshold set at 20 mg BID.
- Market Performance: Mirum's stock closed at $96.53 on Friday, down 0.80%, but is trading at $97.35 in the overnight market, up 0.85%, indicating investor interest in the upcoming trial results.
See More
Mirum Pharmaceuticals to Host Investor Call on VISTAS Study Results
- Investor Call Announcement: Mirum Pharmaceuticals has announced an investor call scheduled for May 4, 2026, at 8:30 a.m. ET to discuss topline results from the VISTAS study on volixibat for patients with primary sclerosing cholangitis (PSC), aimed at enhancing investor understanding of the company's R&D progress.
- Study Results Focus: The call will highlight the findings related to volixibat, an IBAT inhibitor in late-stage development for PSC and primary biliary cholangitis (PBC), which could provide new treatment options for patients, thereby potentially impacting market perception positively.
- Company Overview: Mirum Pharmaceuticals specializes in rare diseases, with a portfolio that includes approved products like LIVMARLI® and CHOLBAM®, demonstrating its commitment to delivering breakthrough therapies for overlooked conditions and showcasing deep expertise in the rare disease sector.
- Clinical Pipeline Insights: Mirum's clinical pipeline features candidates such as brelovitug for chronic hepatitis delta virus and MRM-3379 for Fragile X syndrome, reflecting the company's strategic focus on advancing high-impact medicines through disciplined execution and collaboration within the rare disease ecosystem.
See More
Mirum Pharmaceuticals' AZURE-1 Study Achieves Key Endpoint
- Clinical Trial Success: Mirum Pharmaceuticals reported that in the Phase 2b portion of its AZURE-1 study, brelovitug demonstrated strong antiviral activity at Week 24, with 100% of patients in the 300 mg weekly group and 75% in the 900 mg every four weeks group achieving a virologic response, indicating its effectiveness in treating chronic hepatitis delta virus (HDV).
- Primary Endpoint Achieved: The primary composite endpoint, which includes virologic response and normalization of liver enzyme ALT, was achieved in 45% and 35% of patients in the respective dose groups, while none in the delayed treatment group, highlighting brelovitug's therapeutic potential.
- Good Tolerability: Over the 24-week observation period, continued reductions in viral levels and liver enzyme markers were observed, supporting brelovitug's potential as a standalone therapy for HDV, potentially offering new treatment options for patients.
- Stock Price Fluctuation: Mirum's shares closed at $91.49 on Friday, down 0.50%, reflecting a relatively muted market reaction despite the positive clinical trial results, which may indicate investor caution regarding future studies and market acceptance.
See More
